Headquarters in Provo, Utah
|
|
Type
|
Public |
---|---|
Traded as | NYSE: NUS S&P 400 Component |
Industry | Multilevel marketing |
Founded | 1984 (1984) |
Founder | Blake Roney, Steve Lund, Sandie Tillotson, Nedra Roney |
Headquarters | Provo, Utah, United States |
Area served
|
Worldwide |
Key people
|
Steve Lund (Chairman) M. Truman Hunt (President, CEO, and Director) Ritch N. Wood (Vice President and CFO) |
Products | Personal care, dietary supplements |
Revenue | US$ 2.25 billion (2015) |
Operating income
|
US$ 352.188 million (2014) |
Net income
|
US$ 189.176 million (2014) |
Total assets | US$ 1.614 billion (2014) |
Total equity | US$ 942.438 million (2014) |
Number of employees
|
5,000 (Dec 2014) |
Website | www |
Coordinates: 40°14′00″N 111°39′37″W / 40.233437°N 111.660171°W / 40.233437; -111.660171
Nu Skin Enterprises is an American multilevel marketing company which develops and sells personal care products and dietary supplements (under the Pharmanex brand). Nu Skin was founded in 1984 in Provo, Utah. The company originated in the U.S. and began its first foreign operation in Canada in 1990. One year later, the company began operations in Asia with the opening of Hong Kong. In 1996 the company listed on the New York Stock Exchange. The company markets its products in 54 markets through a network of approximately 1.2 million independent distributors.
In the 1990s, the Federal Trade Commission (FTC) investigated Nu Skin over complaints of its multilevel marketing practices. In 1992, Nu Skin reached settlements with 5 states which had accused the company of deceptive advertising and overstating the income earned by distributors. In 1994, following an investigation by the Federal Trade Commission (FTC), the company paid $1 million and signed a consent decree prohibiting it from making deceptive or unsubstantiated claims about its products. In 1997, the company paid an additional $1.5 million to the FTC to settle ongoing allegations of unsubstantiated promotional claims. In January 2014, the Chinese government announced that it was investigating Nu Skin following a People's Daily newspaper report calling it a "suspected illegal pyramid scheme." In 2016, Nu Skin agreed to pay a $47 Million settlement for operating a pyramid scheme after a being sued by China in a Utah federal court. Nu Skin was also forced to pay another $750,000 for bribing a top Chinese official with funds from Nu Skin's charitable division after a US Securities and Exchange Commission probe.
Under the Nu Skin and Pharmanex brands, the company develops and sells more than 200 personal care products marketed as helping people look and feel younger. In the late 1990s, Nu Skin invested in Big Planet, a multi-level marketing company selling Internet services. The New York Times noted that Big Planet appeared to recruit people "even if they have little knowledge of the technology that they are supposed to be selling." A representative of the company stated: "I believe people who have never touched a computer before can become hugely wealthy in this business."
In 1996, Nu Skin acquired Pharmanex, a dietary-supplement company. A portion of proceeds from some product lines is donated internally to the Nu Skin Force for Good Foundation. The company owns patent on a device developed by Pharmanex called a "BioPhotonic Scanner", which is designed to measure the carotenoid level in skin. According to Women's Health Letter, the device is a "scam" since it is designed merely to help sell more supplements: Nu Skin's 2002 annual report stated: "As customers track their skin carotenoid content, we believe they will be motivated to consistently consume LifePak for longer periods of time".
In 2009, Nu Skin began working with LifeGen Technologies, a genomics company based in Madison, Wisconsin, Nu Skin acquired LifeGen in December, 2011. LifeGen's genetic database aided in the development of Nu Skin's products, launching the ageLOC brand.
Nu Skin Enterprises' utilizes a multi-level marketing business model. Each distributor markets products directly to potential customers, and can also recruit and train customers to become distributors. Distributors are paid from the retail markup on products they are able to sell personally, as well as a performance bonus based on the sales of distributors they have recruited. Nu Skin states that it pays approximately 43 percent of its product revenue in sales compensation.
In 2008, Nu Skin provided partial funding for a scoreboard at Brigham Young University's football stadium.
In the early 1990s, Nu Skin was investigated by the states of Connecticut, Pennsylvania, Florida, Illinois, Ohio, and Michigan over allegations of misleading marketing practices. Ultimately, in 1992 the company settled with 5 of these states, admitting no wrongdoing but agreeing to pay the states' investigative costs, refund disgruntled distributors, and revamp its promotional practices. However, the Connecticut Attorney General did not agree to those terms and sued Nu Skin, charging the company with misleading its distributors and operating a pyramid scheme. Nu Skin admitted to no wrongdoing or violation of law and paid Connecticut $85,000 for consumer-protection programs as part of a settlement.
In 1997, the Attorney General of Pennsylvania sued Nu Skin, alleging that the company operated a pyramid scheme through a subsidiary, QIQ Connections. The Attorney General's office alleged that distributors paid for the right to market technology services which did not, in fact, exist. Nu Skin discontinued the QIQ subsidiary, allowing those who had paid QIQ to transition to Big Planet, another Nu Skin interest marketing Internet technology. The president of Big Planet described the pyramid-scheme allegations as a matter of "a few distributors who in their enthusiasm have been overzealous in some of their marketing activities."
In 2010, Nu Skin was listed among Forbes "100 Most Trustworthy Companies".
In 2012, Stanford University sent a cease and desist letter to halt the use of the name of one of its researchers in Nu Skin's advertising claims. Stanford later released a statement regarding its long-standing, research-based relationship with Nu Skin explaining that the letter was sent to Nu Skin as a request by Stuart Kim a professor at Stanford. Kim requested in the letter that his name be removed from Nu Skin's marketing materials as he is no longer involved with research funded by Nu Skin. However, the letter did not recognize the existing research relationship between Stanford and Nu Skin. Stanford apologized for any misunderstandings that may have resulted.
Also in 2012, Citron Research issued a report "stating that Nu Skin's sales model on mainland China, the fastest growing market in direct-selling, amounted to an illegal multi-level marketing scheme." Nu Skin dismissed the claims, calling its sales model in China kosher and stating that it had no plans to change its business model in China. In January 2014, the Chinese government announced that it planned to investigate Nu Skin for allegedly operating an illegal pyramid scheme, causing the company's stock price to plunge. At least one analyst is optimistic about the outcome. Following the investigation, it was announced in March 2014 that the Chinese government would fine Nu Skin for approximately $540,000 dollars due to illegal sales as well as making false product claims.
In February 2014, a securities fraud class action lawsuit was filed in the United States District Court for the District of Utah against Nu Skin Enterprises, Inc. on behalf of investors who purchased or otherwise acquired the common stock of the Company during the period from July 10, 2013 through January 16, 2014.
The Pharmanex LifePak Anti-Aging supplement was tested by ConsumerLab.com, and was reported as failing the overall review due to failing to clearly indicate its total Vitamin A content per FDA requirements.
In 2011, two Utah-incorporated business entities linked to top executives of Nu Skin each made a $1 million contribution to Restore Our Future, a "Super PAC" established by former aides to US presidential candidate Mitt Romney to support his bid for the White House.
Beginning in 1989 Jason Chaffetz worked as a professional spokesman for the company for about ten years. Chaffetz was elected U.S. Representative of Utah's 3rd congressional district in 2008 and later served as co-chair of the Congressional Dietary Supplement Caucus, a panel within congress that advocates on behalf of the dietary supplement industry, until retiring from Congress in 2017.
Media related to Nu Skin Enterprises at Wikimedia Commons
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-01 | Future report Set alerts | |
Q2 2022 | 2022-08-04 | 0.67 | 0.67 |
Q1 2022 | 2022-05-04 | 0.76 | 0.76 |
Q4 2021 | 2022-02-16 | 1.11 | 1.11 |
Q3 2021 | 2021-11-03 | 0.97 | 0.97 |
Q2 2021 | 2021-08-04 | 1.15 | 1.15 |
Q1 2021 | 2021-05-05 | 0.91 | 0.91 |
Q4 2020 | 2021-02-11 | 1.40 | 1.40 |
Q3 2020 | 2020-11-04 | 0.00 | 0.00 |
Q2 2020 | 2020-08-05 | 0.81 | 0.81 |
2016-07-01 | Boost Price Target | Citigroup Inc. | Buy | $45.00 to $52.00 |
2016-06-17 | Reiterated Rating | Jefferies Group | Hold | $41.00 |
2016-06-16 | Boost Price Target | Pivotal Research | Buy | $55.00 to $60.00 |
2016-06-03 | Initiated Coverage | Jefferies Group | Hold | $41.00 |
2016-04-29 | Boost Price Target | Stifel Nicolaus | Sell | $30.00 to $34.00 |
2016-04-29 | Reiterated Rating | Pivotal Research | Buy | $40.00 to $55.00 |
2016-04-19 | Reiterated Rating | Citigroup Inc. | Buy | $38.00 to $45.00 |
2016-02-12 | Downgrade | Sidoti | Buy to Neutral | |
2016-02-12 | Reiterated Rating | Stifel Nicolaus | Sell | $31.00 to $22.00 |
2016-01-13 | Lower Price Target | Citigroup Inc. | $48.00 to $42.00 | |
2015-12-08 | Reiterated Rating | Canaccord Genuity | Hold | $40.00 |
2015-11-07 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $40.00 |
2015-11-02 | Upgrade | Citigroup Inc. | Neutral to Buy | $65.00 |
2015-10-30 | Reiterated Rating | Canaccord Genuity | Hold | $40.00 |
2015-10-07 | Lower Price Target | Pivotal Research | Buy | $75.00 to $50.00 |
2015-10-07 | Lower Price Target | Bank of America | $44.00 to $40.00 | |
2015-10-07 | Reiterated Rating | Citigroup Inc. | Buy | $54.00 to $48.00 |
2015-10-07 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $49.00 to $40.00 |
2015-10-07 | Lower Price Target | Deutsche Bank | Buy | $60.00 to $55.00 |
2015-10-07 | Lower Price Target | Canaccord Genuity | Sell to Hold | $48.00 to $45.00 |
2015-10-07 | Downgrade | Stifel Nicolaus | Hold to Sell | $35.00 |
2015-10-07 | Lower Price Target | Bank of America Corp. | $44.00 to $40.00 | |
2015-10-07 | Lower Price Target | Deutsche Bank AG | Buy | $60.00 to $55.00 |
2015-08-07 | Reiterated Rating | Deutsche Bank | Buy | $68.00 to $60.00 |
2015-08-07 | Reiterated Rating | Canaccord Genuity | Hold | $47.00 to $48.00 |
2015-07-29 | Reiterated Rating | Canaccord Genuity | Hold | $56.00 to $47.00 |
2015-07-20 | Initiated Coverage | Sterne Agee CRT | Neutral | |
2015-07-10 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $60.00 to $40.00 |
2015-07-09 | Reiterated Rating | Citigroup Inc. | Buy | $56.00 to $55.00 |
2015-05-10 | Reiterated Rating | Stifel Nicolaus | Hold | |
2015-05-07 | Lower Price Target | Citigroup Inc. | Buy | $65.00 to $56.00 |
2015-05-07 | Boost Price Target | Canaccord Genuity | Hold | $56.00 to $60.00 |
2015-04-23 | Boost Price Target | Canaccord Genuity | Hold | $51.00 to $60.00 |
2015-02-11 | Upgrade | Citigroup Inc. | Neutral to Buy | |
2015-02-06 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $50.00 to $53.00 |
2015-02-06 | Boost Price Target | Citigroup Inc. | Neutral to Buy | $49.00 to $65.00 |
2015-02-05 | Set Price Target | Pivotal Research | Buy | $75.00 |
2015-02-05 | Reiterated Rating | BTIG Research | Hold | |
2014-12-16 | Lower Price Target | Citigroup Inc. | Neutral | $46.00 to $44.00 |
2014-12-15 | Lower Price Target | Bank of America | Underperform | $46.00 to $43.00 |
2014-11-25 | Initiated Coverage | Citigroup Inc. | Neutral | $45.00 |
2014-11-19 | Initiated Coverage | BTIG Research | Neutral | |
2014-11-06 | Reiterated Rating | Bank of America | Underperform | $50.00 to $46.00 |
2014-11-06 | Reiterated Rating | Canaccord Genuity | Hold | $53.00 |
2014-11-05 | Reiterated Rating | Deutsche Bank | Buy | |
2014-10-20 | Initiated Coverage | Pivotal Research | Buy | $75.00 |
2014-08-07 | Reiterated Rating | Deutsche Bank | Buy | $110.00 to $70.00 |
2014-08-07 | Reiterated Rating | Canaccord Genuity | Hold | $92.00 to $53.00 |
2014-08-07 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $100.00 to $50.00 |
2014-07-18 | Downgrade | Evercore ISI | Neutral to Underperform | $63.00 |
2014-07-18 | Downgrade | Bank of America | Neutral to Underperform | $63.00 |
2014-05-12 | Upgrade | Ned Davis Research | Neutral to Buy | |
2014-05-07 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $115.00 to $100.00 |
2014-03-24 | Boost Price Target | Canaccord Genuity | Hold | $78.00 to $93.00 |
2014-03-04 | Lower Price Target | Deutsche Bank | $115.00 to $110.00 | |
2014-03-04 | Lower Price Target | Canaccord Genuity | $86.00 to $78.00 | |
2014-03-04 | Boost Price Target | Bank of America | $2.00 to $85.00 | |
2014-03-03 | Lower Price Target | Wedbush | $105.00 | |
2014-02-24 | Upgrade | Ned Davis Research | Neutral to Buy | |
2014-02-10 | Downgrade | Ned Davis Research | Buy to Neutral | |
2014-02-10 | Reiterated Rating | Sidoti | Buy | |
2014-02-03 | Reiterated Rating | Deutsche Bank | Buy | |
2014-01-22 | Reiterated Rating | Deutsche Bank | Buy | |
2014-01-17 | Downgrade | Bank of America | Buy to Neutral | $94.00 |
2014-01-16 | Downgrade | Canaccord Genuity | Buy to Hold | $140.00 to $104.00 |
2014-01-13 | Reiterated Rating | Deutsche Bank | Buy | $130.00 to $150.00 |
2013-11-22 | Reiterated Rating | Deutsche Bank | Positive | |
2013-11-22 | Boost Price Target | Canaccord Genuity | $120.00 to $140.00 | |
2013-11-22 | Boost Price Target | JPMorgan Chase & Co. | $130.00 to $144.00 | |
2013-11-18 | Downgrade | Ned Davis Research | Buy to Neutral | |
2013-10-23 | Boost Price Target | Wedbush | Outperform | $103.00 to $130.00 |
2013-10-23 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $97.00 to $130.00 |
2013-10-23 | Boost Price Target | Canaccord Genuity | Buy | $99.00 to $120.00 |
2013-10-23 | Boost Price Target | Deutsche Bank | Buy | $110.00 to $127.00 |
2013-10-22 | Upgrade | Sidoti | Neutral to Buy | |
2013-10-22 | Boost Price Target | DA Davidson | Buy | $110.00 to $150.00 |
2013-10-09 | Upgrade | DA Davidson | Neutral to Buy | $110.00 |
2013-10-08 | Boost Price Target | Deutsche Bank | Buy | $100.00 to $110.00 |
2013-09-27 | Downgrade | Sidoti | Buy to Neutral | |
2012-05-17 | Reiterated | Stifel Nicolaus | Buy | $60 to $51 |
2011-10-26 | Reiterated | Stifel Nicolaus | Buy | $46 to $51 |
2011-08-31 | Upgrade | Wedbush | Neutral to Outperform | $40 to $48 |
2016-07-01 | Boost Price Target | Citigroup Inc. | Buy | $45.00 to $52.00 |
2016-06-17 | Reiterated Rating | Jefferies Group | Hold | $41.00 |
2016-06-16 | Boost Price Target | Pivotal Research | Buy | $55.00 to $60.00 |
2016-06-03 | Initiated Coverage | Jefferies Group | Hold | $41.00 |
2016-04-29 | Boost Price Target | Stifel Nicolaus | Sell | $30.00 to $34.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In NUS 173 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
STATE STREET CORP | 9.47M |
Vanguard Group, Inc | 5.90M |
BlackRock Inc. | 5.76M |
BlackRock Fund Advisors | 4.27M |
WELLINGTON MANAGEMENT CO LLP | 3.49M |
RENAISSANCE TECHNOLOGIES LLC | 2.54M |
DIMENSIONAL FUND ADVISORS LP | 1.92M |
BlackRock Institutional Trust Company, N.A. | 1.39M |
Capital World Investors | 1.10M |
GEODE CAPITAL MANAGEMENT, LLC | 1.01M |
Aristotle Capital Boston, LLC | 0.76M |
Invesco Ltd. | 0.71M |
MORGAN STANLEY | 0.71M |
ProShare Advisors LLC | 0.67M |
NORTHERN TRUST CORP | 0.67M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
HUNT M TRUMAN President & CEO | 0.97% (575559) | NUS / |
WOOD RITCH N Chief Financial Officer | 0.20% (120497) | NUS / |
NAPIERSKI RYAN S Pres Global Sales & Operations | 0.11% (64602) | NUS / |
CAMPBELL DANIEL W | 0.11% (63753) | NUS / |
CHANG JOSEPH Y Chief Scientific Officer | 0.10% (59416) | NUS / |
Schwerdt Scott E President, Americas Region | 0.09% (53335) | NUS / |
Chard Daniel R President | 0.08% (48111) | MED / NUS / |
DORNY D MATTHEW General Counsel | 0.08% (46371) | NUS / |
LIPMAN ANDREW D | 0.08% (44455) | CRTN / NUS / |
Thomas Pisano R. | 0.07% (42437) | NUS / |
LUND STEVEN Exec. Chairman of the Board | 0.07% (40000) | NUS / |
Andersen Nevin N | 0.03% (16285) | NUS / |
Lawrence Mark H Chief Financial Officer | 0.02% (10162) | NUS / |
OFFEN NEIL H | 0.02% (9226) | NUS / |
Negron Patricia | 0.01% (7592) | NUS / |
WOODBURY EDWINA D | 0.01% (4813) | NUS / RSH / |
Shen Zhequing | 0.01% (3456) | NUS / |